International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age10-70
SponsorInsel Gruppe AG, University Hospital Bern
About this trial
Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (SPHYNCS) is a cohort study on disease presentation and long-term course with an exploratory approach to detect biomarkers.
Eligibility criteria
Qualifiers
Subjective complaints of Excessive daytime sleepiness (EDS) and/or Hypersomnia (H) as defined above
EDS and/or H present daily or almost daily for at least 1 month prior to the consultation
Ability and consent to undergo electrophysiological routine assessment
Ability to give informed consent
Disqualifiers
Apnea index (AI) > 10 if on OSA treatment or untreated; or
Clinically significant hypoventilation; or
Noncompliance with primary OSA therapy
except if NT1 has been diagnosed including decreased or missing cerebrospinal fluid (CSF) hypocretin
Trial design
Treatments tested in this trial
- Not listed
Trial groups
600 Participants
are grouped into 4 trial groupsSponsors and collaborators
Insel Gruppe AG, University Hospital Bern
Lead sponsor
Klinik Barmelweid
Collaborator
Zentrum für Schlafmedizin Basel
Collaborator
Ospedale Regionale di Lugano
Collaborator
Cantonal Hospital of St. Gallen
Collaborator
Zurzach Care Klinik für Schlafmedizin
Collaborator
University Children's Hospital, Zurich
Collaborator
University Children's Hospital Basel
Collaborator
Centre Lausannios de Sommeil
Collaborator
Private Universität Witten-Herdecke and Orfea Fachklinik für Schlafmedizin, Witten, Germany
Collaborator
Leiden University Medical Center, Leiden, Netherlands
Collaborator
University of Bologna
Collaborator
Source ClinicalTrials.gov